久久无码人妻一区二区三区午夜_久久久久精品久久久久影院蜜桃_亚洲综合欧美色五月俺也去_交换娇妻呻吟声不停中文字幕

南京科佰生物科技有限公司

當前位置:南京科佰生物科技有限公司>>藥靶細胞株>>kinase激酶細胞株>> CBP73198KIF5B(E15)-RET(E12) V804L/BaF3

KIF5B(E15)-RET(E12) V804L/BaF3

參  考  價:面議
具體成交價以合同協(xié)議為準

產(chǎn)品型號CBP73198

品牌cobioer/科佰生物

廠商性質(zhì)代理商

所在地南京市

更新時間:2022-08-02 16:51:29瀏覽次數(shù):737次

聯(lián)系我時,請告知來自 化工儀器網(wǎng)
供貨周期 現(xiàn)貨 規(guī)格 T-25 Flask
貨號 CBP73198 應(yīng)用領(lǐng)域 生物產(chǎn)業(yè)
主要用途 僅限科研使用
KIF5B(E15)-RET(E12) [V804L]/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO
CBP73198
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804L]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of KIF5B-RET [V804L]/BaF3

CBP73198 WB.png


2. Sanger of KIF5B-RET [V804L]/BaF3

CBP73198 sanger1.png


CBP73198 sanger2.png


3. Anti-proliferation assay

CBP73198 fig.jpg

Figure 4.CTG Proliferation Assay of BaF3 KIF5B-Ret (S) V804L Cells (C1).




CD74-ROS1 G2032R BaF3

CD74-ROS1 [G2032R] BaF3

CD74-ROS1 L2086F BaF3

CD74-ROS1 [L2086F] BaF3

KRAS G12D&Y96C BaF3

KRAS [G12D&Y96C] BaF3

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標簽:
保存成功

(空格分隔,最多3個,單個標簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復您~

以上信息由企業(yè)自行提供,信息內(nèi)容的真實性、準確性和合法性由相關(guān)企業(yè)負責,化工儀器網(wǎng)對此不承擔任何保證責任。

溫馨提示:為規(guī)避購買風險,建議您在購買產(chǎn)品前務(wù)必確認供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。

撥打電話
在線留言
主站蜘蛛池模板: 威远县| 舒城县| 房山区| 西和县| 湘乡市| 张家川| 灵璧县| 张北县| 石首市| 沈丘县| 绥棱县| 民丰县| 合山市| 梅河口市| 鄱阳县| 宜兴市| 大丰市| 东乌| 桐城市| 张家川| 松潘县| 郴州市| 彰化县| 綦江县| 陇川县| 海淀区| 新巴尔虎右旗| 合川市| 通辽市| 宝丰县| 衡南县| 望谟县| 海城市| 娱乐| 济阳县| 岗巴县| 崇仁县| 霍州市| 罗江县| 蓬莱市| 新乐市|